Novartis AG
EURO STOXX 600Last update: May 9, 2026 at 09:32
Dividend Safety Rating
NOVN.SW's dividend appears safe and well-supported. Strengths include a 66.3% earnings payout ratio & 54.4% fcf payout ratio. Areas of concern: 0.8x current ratio & Volatile profit margin stability. The dividend has been growing at a 7.32% 5-year CAGR.
Based on 15 of 15 metrics
Strengths
- Interest Coverage: 15.3xEarnings cover interest payments many times over.
- Return on Equity: 34.9%Strong return on equity reflects efficient profit generation.
- Operating Margin: 30.5%Healthy operating margin provides a wide buffer.
Risks
- Current Ratio: 0.8xLimited short-term liquidity to meet obligations.
- Profit Margin Stability: VolatileProfit margins have been volatile.
Payout & Coverage
SafeBalance Sheet
CautionProfitability
SafeDividend Track Record
Very SafeAbout Novartis AG
Novartis AG is a Swiss multinational pharmaceutical corporation headquartered in Basel, one of the world's largest manufacturers of innovative medicines. Formed in 1996 through the historic merger of Ciba-Geigy and Sandoz, it originated from pioneering Swiss chemical firms dating back to the late 19th century, known for breakthroughs like DDT's insecticidal properties and early pharmaceuticals. In 2023, Novartis restructured by spinning off its generics division, Sandoz, to concentrate on the Innovative Medicines division, focusing on cutting-edge therapeutic areas including oncology, immunology, cardiovascular-renal-metabolic diseases, neuroscience, rare diseases, and ophthalmology. The company employs advanced modalities such as biotherapeutics, gene and cell therapies, radioligand therapy, and xRNA therapeutics, with a robust pipeline featuring late-stage programs and partnerships in AI-driven drug discovery and molecular glues. Novartis operates in approximately 140 countries, reaching millions of patients with key products like Gleevec for leukemia, Entresto for heart failure, Cosentyx for psoriasis, and Kymriah for leukemia via CAR-T therapy. Through its Novartis Institutes for BioMedical Research, it drives global R&D efforts, significantly influencing the pharmaceutical industry's innovation landscape.
Dividend Overview
Dividend Yield
3.26%
Annual Dividend
CHF 3.70
Frequency
Annual
Payout Ratio
66.26%
FCF Payout Ratio
54.39%
Stock Price
CHF 113.36
52-Week Range
CHF 87.89 – CHF 131.00
Dividend History (2016–2025)
NOVN.SW annual dividend per share and yield history
Earnings & Profitability
NOVN.SW earnings per share and net profit margin
Key Dates
Last Ex-Dividend Date
March 10, 2026
Last Payment Date
March 13, 2025
Dividend Growth
3-Year Dividend CAGR
10.65%
5-Year Dividend CAGR
7.32%
10-Year Dividend CAGR
4.91%
3-Year Total Growth
35.49%
5-Year Total Growth
42.37%
10-Year Total Growth
61.54%
Income Calculator
Similar Dividend Stocks
Frequently Asked Questions
What is NOVN.SW's current dividend yield?
When is NOVN.SW's next dividend payment date?
How much does NOVN.SW pay in dividends per year?
Has NOVN.SW been increasing its dividend?
Is NOVN.SW's dividend safe?
How is NOVN.SW's Dividend Safety Rating calculated?
Want to understand how we rate dividend safety? Read our full methodology
Track NOVN.SW Dividends with OnlyDividends
What will NOVN.SW actually pay you after taxes? Track every payout, get notified on payment dates, and stop guessing.
This page is not investment advice. The content is for informational purposes only and should not be construed as a recommendation to buy, sell, or hold any security. Always do your own research and consult a qualified financial advisor before making investment decisions.
Financial data, including dividend history, earnings, balance sheet metrics, and the Dividend Safety Rating, is provided for informational purposes only. Data may be delayed or differ from official filings. Past performance does not guarantee future results. Always verify with official sources before making investment decisions.
Market data provided by Twelve Data.